Regeneron Pharmaceuticals's operating income was $3.58 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), down 10.3% from fiscal 2024.
In the third quarter of fiscal 2026 (the three months to 30 Sep 2026) it was $2.05 billion, up 99.5% from a year earlier.
Over the four quarters to 30 Sep 2026, operating income was $4.86 billion.
From Regeneron Pharmaceuticals's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.
Fiscal 2025
$3.58B
−10.3%
Q3 FY2026
$2.05B
+99.5% on a year
Growth over 9 years
+11.6%
a year, FY 2016–FY 2025
Operating income by fiscal year
Change on the year before, under each year. From FY 2016 to FY 2025, Regeneron Pharmaceuticals's operating income went from $1.33 billion to $3.58 billion, a compound annual change of +11.6%; the highest was $8.95 billion in FY 2021.
Regeneron Pharmaceuticals operating income, fiscal years
Period
FY 2016
FY 2017
FY 2018
FY 2019
FY 2020
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Operating income
$1.33B
$2.08B
$2.53B
$2.21B
$3.58B
$8.95B
$4.74B
$4.05B
$3.99B
$3.58B
Period end
31 Dec 2016
31 Dec 2017
31 Dec 2018
31 Dec 2019
31 Dec 2020
31 Dec 2021
31 Dec 2022
31 Dec 2023
31 Dec 2024
31 Dec 2025
Operating income by quarter
The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.
Operating income is the profit from the company's operations: revenue less the cost of sales and operating expenses, before interest and income tax. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.
Regeneron Pharmaceuticals's other figures
Operating income of comparable companies
Everything on REGN, in the terminal.
Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.